Garo H. Armen Ph.D.
Net Worth

Last updated:

What is Garo H. Armen Ph.D. net worth?

The estimated net worth of Dr. Garo H. Armen Ph.D. is at least $27,331,602 as of 15 Feb 2024. He owns shares worth $2,879,457 as insider, has earned $1,982,145 from insider trading and has received compensation worth at least $22,470,000 in Agenus Inc..

What is the salary of Garo H. Armen Ph.D.?

Dr. Garo H. Armen Ph.D. salary is $1,070,000 per year as Founder, Executive Chairman & Chief Executive Officer in Agenus Inc..

How old is Garo H. Armen Ph.D.?

Dr. Garo H. Armen Ph.D. is 72 years old, born in 1953.

What stocks does Garo H. Armen Ph.D. currently own?

As insider, Dr. Garo H. Armen Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Agenus Inc. (AGEN) Founder, Executive Chairman & Chief Executive Officer 625,969 $4.6 $2,879,457

What does Agenus Inc. do?

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

AGEN logo
AGEN
Agenus Inc.
$4.6

Garo H. Armen Ph.D. insider trading

Agenus Inc.

Dr. Garo H. Armen Ph.D. has made 7 insider trades between 2004-2024, according to the Form 4 filled with the SEC. Most recently he purchased 500,000 units of AGEN stock worth $324,000 on 15 Feb 2024.

The largest trade he's ever made was exercising 2,150,976 units of AGEN stock on 16 Aug 2011. As of 15 Feb 2024 he still owns at least 625,969 units of AGEN stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 500,000 $0.65 $324,000
Sale
Common Stock 119,178 $3.36 $400,438
Sale
Stock Option, right to buy 82,107 $3.36 $275,880
Option
Common Stock 82,107 $6.5 $533,696
Option
Stock Option, right to buy 119,178 $3.36 $400,438
Option
Stock Option, right to buy 119,178 $3.36 $400,438
Purchase
Common Stock 40,388 $3.61 $145,841
Purchase
Common Stock 59,612 $3.51 $209,238
Purchase
Common Stock 29,456 $3.3 $97,058
Purchase
Common Stock 70,544 $3.37 $237,451
Purchase
Common Stock 50,000 $3.28 $163,950
Purchase
Common Stock 50,000 $3.28 $163,950
Purchase
Common Stock 50,000 $3.28 $163,950
Purchase
Common Stock 200,000 $4.03 $805,600
Sale
Common Stock 85,224 $4.57 $389,644
Sale
Common Stock 134,352 $4.61 $618,825
Purchase
Common Stock 100,000 $5.03 $503,000
Purchase
Common Stock 16,666 $2.99 $49,765
Purchase
Common Stock 2,150,976 $0.51 $1,096,998
Sale
Common Stock 87,628 $0.79 $69,051
Sale
Common Stock 99,683 $1.62 $161,287
Sale
Common Stock 38,015 $1.76 $67,020
Purchase
Common Stock 25,000 $1.97 $49,250
Purchase
Common Stock 1,708,717 $3 $5,126,151
Purchase
Common Stock 50,000 $2.33 $116,550
Purchase
Common Stock 10,000 $2.03 $20,290
Purchase
Common Stock 15,000 $2.01 $30,090
Purchase
Common Stock 10,000 $2 $20,000
Purchase
Common Stock 25,000 $1.91 $47,825
Purchase
Common Stock 25,000 $1.83 $45,750
Purchase
Common Stock 25,000 $1.83 $45,750
Purchase
Common stock 50,000 $1.93 $96,500
Option
Stock Option (right to buy)0 51,610 $1.45 $74,835
Option
Common Stock 51,610 $1.45 $74,835
Purchase
Common Stock 25,000 $6.39 $159,750
Purchase
Common Stock 25,000 $5.62 $140,375
Purchase
Common Stock 25,000 $5.62 $140,375
Purchase
Common Stock 100,000 $4.74 $474,300

Agenus key executives

Agenus Inc. executives and other stock owners filed with the SEC: